PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
25-Sep-2024 Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers Lantern Pharma
25-Sep-2024 Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology Orion
25-Sep-2024 Univo IRB Launches Canadian Research Ethics Board Review Services for Clinical Trials in North America Univo IRB
25-Sep-2024 Combination treatment improves response to immunotherapy for lung cancer Francis Crick Institute
25-Sep-2024 Panthera moves back into recruiting and running commercial oncology clinical trials in the UK Panthera Biopartners
25-Sep-2024 Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia CSL Vifor
25-Sep-2024 HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda HUTCHMED
25-Sep-2024 Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia Nxera Pharma
25-Sep-2024 Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy Santhera Pharmaceuticals
25-Sep-2024 Medacta Group SA reports revenue growth of 14.3% at constant currency and adjusted EBITDA margin 26.9%, or 28.1% at constant currency in 1H 2024. Medacta Group SA
24-Sep-2024 Very successful human clinical trial with the innovative antibacterial surface-treated implants receives approval for quick end of recruitment. aap Implantate AG
24-Sep-2024 Medacta NextAR Rod Optimizer, a Disruptive Technology Redefining Rod Management in Spine Surgery, wins the 2024 Spine Technology Award from Orthopedics This Week Medacta Group SA
24-Sep-2024 Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel) Lonza Group AG
24-Sep-2024 Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs Mabylon AG
24-Sep-2024 Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops Marinomed Biotech AG
23-Sep-2024 Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia Teva Pharmaceutical Industries Ltd
23-Sep-2024 Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant Sanofi
23-Sep-2024 Almirall to present new data on biologics for psoriasis and atopic dermatitis and celebrates 80 years of innovation at the EADV congress Almirall
23-Sep-2024 Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia Teva Pharmaceutical Industries Ltd
23-Sep-2024 Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024 Heidelberg Pharma AG